Pfizer's Sigvotatug Vedotin Misses Overall Survival Goal in Phase 3 Lung Cancer Trial, Salvaging a Signal in Second-Line Patients
Pfizer's integrin beta-6 ADC failed to beat docetaxel on overall survival across the full SigVie-002 population, but showed a stronger trend in the two-thirds of patients with one prior line of therapy.
Overview
Pfizer’s experimental antibody-drug conjugate sigvotatug vedotin failed to extend overall survival across the full population of a Phase 3 lung cancer trial, the company announced on June 22, 2026. According to Pfizer, the drug “did not show a statistically significant improvement in the primary endpoint of overall survival (OS) compared to docetaxel” in the SigVie-002 study. But the company pointed to a more favorable result in a large subgroup of patients as a reason to keep advancing the program.
What We Know
The trial, Pfizer said, is the “Phase 3 SigVie-002 study (previously known as Be6A Lung-01),” which enrolled previously treated patients with “locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC).” Sigvotatug vedotin is described as “an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC).” The comparator arm received docetaxel, a long-standing chemotherapy option in this setting.
The headline result was a miss on the study’s main goal. As reported by BioSpace, “In the overall population, sigvotatug vedotin did not show a statistically significant improvement in the primary endpoint of overall survival (OS) compared to docetaxel.”
The company’s case for continuing rests on a subgroup. According to Pfizer, “in patients who received only one prior line of systemic therapy, which represents two-thirds of the study population, a stronger trend was observed for OS and progression-free survival (PFS) for sigvotatug vedotin over docetaxel.” Pfizer described these as second-line patients in its commentary.
Jeff Legos, Pfizer’s Chief Oncology Officer, framed the result around that group. “Although the overall study results did not demonstrate superiority over docetaxel, it is encouraging that second-line patients treated with sigvotatug vedotin achieved strong efficacy outcomes compared to an established standard of care, alongside a manageable safety profile,” he said, according to Pfizer.
Solange Peters, M.D., PhD, Chair of Medical Oncology & Thoracic Cancers Clinic at Lausanne University Hospital, Switzerland, offered a similar reading. “Although the study did not meet its overall survival endpoint, in second-line patients the data suggest a clinically meaningful survival benefit for sigvotatug vedotin over docetaxel, supporting continued scientific evaluation of sigvotatug vedotin in earlier lines in combination with immunotherapy,” she said, per Pfizer.
On tolerability, Pfizer said “the safety profile of sigvotatug vedotin was manageable and consistent with prior studies.”
The target itself is part of the rationale. The drug is directed at integrin beta-6, which Investing News Network reported “is expressed on approximately 90% of tumors” in NSCLC and “is associated with poor prognosis.” Sigvotatug vedotin came to Pfizer through its purchase of Seagen; “since the acquisition of Seagen, Pfizer has continued to advance a broad ADC portfolio,” according to Investing News Network.
What Comes Next
Pfizer said full results have not yet been presented publicly. “Detailed results from SigVie-002 will be submitted for presentation at a future medical congress,” the company said, according to Pfizer.
The company is also testing the drug earlier in the treatment sequence. Pfizer pointed to “an ongoing Phase 3 study evaluating sigvotatug vedotin + pembrolizumab in 1L NSCLC with PD-L1 tumor proportion score (TPS) ≥50%,” along with combination work involving a bispecific antibody targeting PD-1 and VEGF. Separately, Investing News Network noted Pfizer’s pipeline includes “fetrastobart vedotin, a PD-L1–directed ADC currently in Phase 3 in NSCLC.”
What We Don’t Know
Pfizer’s topline release did not disclose the numerical magnitude of any survival difference, hazard ratios, confidence intervals, or the size of the trial’s enrollment. Because the subgroup result was described only as a “stronger trend” and the overall study did not reach statistical significance, it is not yet clear whether the second-line data would support a regulatory filing on their own. The company has not stated whether it will seek approval in the previously treated setting or focus instead on the first-line combination studies still underway. Full efficacy and safety figures await presentation at a future medical meeting.